Cryoanalgesia as a Treatment for Spasticity

Cryoanalgesia is a minimally invasive technique originally developed for pain management that involves the controlled freezing and thawing of peripheral nerves. Emerging clinical evidence suggests that cryoneurolysis may be an effective treatment approach for spasticity and spasticity-related pain by targeting peripheral motor nerves while preserving surrounding tissue and allowing for predictable nerve regeneration.

Spasticity remains a persistent clinical challenge, particularly in patients where pharmacologic therapies provide limited functional improvement or introduce systemic burden. In these situations, treatment strategies often aim to reduce muscle overactivity while preserving function and supporting rehabilitation outcomes.

Cryoneurolysis is being investigated as a minimally invasive technique to address focal spasticity through targeted peripheral nerve intervention. Recent clinical reports describe its use in modulating motor nerve activity, with observed reductions in muscle tone, improvements in range of motion, and decreased spasticity-related pain.

By inducing a controlled, reversible interruption of nerve conduction while preserving the underlying nerve structure, cryoneurolysis allows for predictable regeneration over time. This characteristic has been highlighted in recent case series and reports describing sustained functional improvements and clinically meaningful reductions in Modified Ashworth Scale (MAS) scores following treatment.

For interventional pain physicians, this approach introduces a peripheral nerve–focused strategy that may complement existing techniques used in the management of spasticity and associated pain, reflecting a growing interest in peripheral motor nerve modulation.

How Cryoanalgesia May Support Spasticity Management?

 In the context of focal spasticity, targeting peripheral motor pathways has been proposed as a complementary strategy to central and systemic approaches.

Spasticity is a motor phenomenon associated with disorders of the central nervous system that can significantly affect active and passive function, mobility, and quality of life. Commonly seen in conditions such as stroke, multiple sclerosis, cerebral palsy, traumatic brain injury, and spinal cord injury, spasticity remains challenging to manage despite the availability of pharmacological, physical, and surgical treatment options—each of which carries important limitations. (“Cryoneurolysis: A Novel Treatment for Management of Spasticity. Presentation of a Case Series”)

By selectively targeting peripheral motor nerves, cryoanalgesia may help improve range of motion, reduce pain associated with muscle hyperactivity, and facilitate participation in rehabilitation programs. This technique has been associated with reductions in muscle hyperactivity and spasticity-related pain while sparing surrounding tissue, contributing to improvements in joint range of motion (ROM) and functional mobility.

Cryoneurolysis may be considered as part of multimodal spasticity management strategies alongside:

• Rehabilitation
• Physical therapy
• Other interventional approaches

Understanding the Target: Peripheral Motor Nerves

Effective cryoneurolysis in spasticity requires precise identification of the motor nerves contributing to abnormal muscle tone. Common targets vary depending on the clinical presentation but may include nerves supplying:

• Upper limb flexors (e.g., musculocutaneous, median, radial, and ulnar nerves)
• Lower limb muscles (e.g., tibial, femoral, or obturator nerve branches)

By selectively interrupting motor nerve conduction, cryoanalgesia reduces excessive muscle contraction while preserving surrounding tissue and sensory pathways when appropriately targeted.

Clinical Benefits and Considerations

Potential benefits include:

• Targeted reduction of muscle hyperactivity through peripheral nerve modulation
• Improvement in joint range of motion (ROM) and limb positioning
• Decrease in spasticity-related pain
• Minimally invasive approach with limited recovery time
• Reversible effect due to preserved nerve structure
• Potential for functional improvement when combined with rehabilitation
• Reduced reliance on systemic therapies or repeated injections

Clinical considerations include:

• Outcomes depend on accurate nerve identification and procedural technique
• Effects are temporary due to nerve regeneration
• Repeat procedures may be required
• Evidence continues to evolve compared to more established spasticity treatments

Who May Benefit from Cryoneurolysis?

Patients experiencing focal spasticity and spasticity-related pain may be candidates for cryoneurolysis, particularly when symptoms interfere with mobility, positioning, rehabilitation, or daily function. Cryoneurolysis may be considered in patients with spasticity associated with:

• Stroke
• Traumatic brain injury
• Spinal cord injury
• Multiple sclerosis
• Cerebral palsy
• Brain tumors

Evidence Supporting Cryoneurolysis for Spasticity

Emerging clinical evidence suggests that cryoneurolysis may contribute to reductions in spasticity and associated symptoms, particularly in cases of focal involvement. While current data remain limited compared to established therapies, recent publications provide insight into its potential role in clinical practice.
Several case series and clinical reports describe:

• Reductions in muscle tone, as measured by Modified Ashworth Scale (MAS) scores
• Improvements in joint range of motion (ROM) and limb positioning
• Decreased spasticity-related pain
• Increased participation in rehabilitation and functional activities

A 2025 case series on percutaneous cryoneurolysis reported clinically meaningful reductions in spasticity, along with functional improvements across treated patients (Archives of Rehabilitation Research and Clinical Translation).

A July 2025 publication described cryoneurolysis as a novel therapeutic approach, with reported reductions in muscle tone and improvements in patient-reported outcomes (PMC Article).

A September 2025 case report in multiple sclerosis showed sustained functional gains and cost-effectiveness, suggesting long-term clinical value in selected patients. (ScienceDirect)

Earlier literature on cryoneurotomy as a mini-invasive therapy supports its safety profile and repeatability, proposing structured approaches for integrating the technique into clinical practice. (PubMed)

A case report in multiple sclerosis highlighted sustained functional gains in a selected patient population (ScienceDirect).

Earlier literature on cryoneurotomy also supports its safety profile and repeatability as a minimally invasive intervention (PubMed)

These findings suggest cryoneurolysis may represent a promising minimally invasive option for focal spasticity management. However, further research is needed to confirm its effectiveness and long-term outcomes.

FAQS

Q1: What type of cryoanalgesia system can be used for spasticity-related procedures?

Cryoneurolysis procedures may be performed using dedicated cryoanalgesia systems such as the PainBlocker™ Cryoanalgesia System. A cryoanalgesia system designed to support precise targeting through controlled freezing cycles.

Q2: How long do the effects of cryoneurolysis last in spasticity management?

The effects of cryoneurolysis are temporary and depend on the rate of nerve regeneration. Clinical reports suggest that reductions in muscle tone and associated symptoms may persist for several weeks to months, although duration can vary based on the nerve targeted and patient-specific factors.

Q3: Which nerves can be targeted in cryoneurolysis for spasticity?

Target nerves vary depending on the clinical presentation and the muscles involved. Common targets may include branches of the musculocutaneous, median, radial, ulnar, tibial, femoral, or obturator nerves. Accurate anatomical identification is essential to achieve the desired effect on muscle tone.